hcplive.com
Cure8 news brief
Why This Matters
Deep remission is an emerging treatment target in Crohn’s disease that combines symptoms and objective measures. A meaningful proportion of patients in VIVID-1 achieved corticosteroid-free deep remission with mirikizumab at 1 year, and those who did were likely to also report improved quality of life.
Who Should Pay Attention
Adults with moderately to severely active Crohn’s disease; people considering or receiving biologic therapy; clinicians treating IBD; researchers interested in IL-23 therapies and trial endpoints.
Study Snapshot
Story typeResearch news
Evidence typePhase 3 clinical trial
Source depthFull source text
What To Know
About 1 in 5 patients with moderately to severely active Crohn’s disease treated with mirikizumab (Omvoh) reached corticosteroid-free deep remission at 1 year in a post hoc analysis of the phase 3 VIVID-1 trial presented at UEG Week 2026.
Rates were higher in patients without prior biologic failure and most patients who reached deep remission also met an IBD quality-of-life remission threshold. The analysis compared two definitions of deep remission (a CDAI-based definition and a PRO-based definition combining stool frequency, abdominal pain, and endoscopic remission).
Both definitions produced similar mirikizumab deep-remission rates (~20% at week 52) versus very low rates with placebo. The analysis included 579 mirikizumab-treated and 199 placebo-treated patients. The authors note higher response in patients treated earlier in disease course and without prior biologic failure.
This report summarizes a conference poster and a post hoc analysis; findings are drawn from the VIVID-1 trial dataset presented at UEG Week and described in the HCPLive article.
Keep In Mind
This is a post hoc analysis from a phase 3 trial presented as a conference poster; post hoc results are hypothesis-generating and should be interpreted with caution. The HCPLive article summarizes the poster and related trial publications; it does not replace reading the full peer-reviewed report.
Mirikizumab was FDA-approved for Crohn’s disease in January 2025 based on VIVID-1 primary results.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationhcplive.com
PublisherHCPLive
AuthorsStefan Schreiber, MD
Indexed viaGoogle News
Source typeWeb article
PublishedOct 15, 2026, 5:04 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Mirikizumab Sustains Long-Term Efficacy in Crohn's Disease | AGA - DocWire News
This study suggests mirikizumab can maintain endoscopic and symptomatic improvements for up to two years in many patients with Crohn’s disease, and that IV reinduction can recover response in a subset of 1-year...
VIVID-2: Omvoh demonstrates ‘continued durability,’ safety in Crohn’s disease at 2 years
Longer-term data help patients and clinicians understand whether an initial response to a new biologic (mirikizumab) is likely to last and whether safety findings remain acceptable over two years.
Eli Lilly presents positive results from VIVID-2 open-label extension study of Omvoh to treat Crohn's disease at Crohn's and Colitis Congress
These are multi‑year clinical results for a newly approved IL‑23p19 inhibitor (mirikizumab) showing sustained clinical and endoscopic benefit for many patients with moderate‑to‑severe Crohn’s disease, including some who...